Directly to content
  1. Publishing |
  2. Search |
  3. Browse |
  4. Recent items rss |
  5. Open Access |
  6. Jur. Issues |
  7. DeutschClear Cookie - decide language by browser settings

Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia

Wang, Shuzhen ; Zhang, Xin ; Han, Tao ; Xie, Wen ; Li, Yonggang ; Ma, Hong ; Liebe, Roman ; Weng, Honglei ; Ding, Hui-Guo

In: BMC Gastroenterology, 18 (2018), Nr. 137. pp. 1-8. ISSN 1471-230X

[img]
Preview
PDF, English
Download (982kB) | Lizenz: Creative Commons LizenzvertragTolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia by Wang, Shuzhen ; Zhang, Xin ; Han, Tao ; Xie, Wen ; Li, Yonggang ; Ma, Hong ; Liebe, Roman ; Weng, Honglei ; Ding, Hui-Guo underlies the terms of Creative Commons Attribution 3.0 Germany

Citation of documents: Please do not cite the URL that is displayed in your browser location input, instead use the DOI, URN or the persistent URL below, as we can guarantee their long-time accessibility.

Abstract

Background: Although tolvaptan treatment improves hyponatremia, only few studies have investigated whether tolvaptan actually benefits the survival of cirrhotic patients. This study evaluated the impact of tolvaptan on six-month survival of decompensated cirrhotic patients with and without hyponatremia.

Methods: Two hundred forty-nine decompensated cirrhotic patients with or without hyponatremia were enrolled in a multicenter cohort study. Patients were divided into two groups according to receiving either tolvaptan or placebo treatment for 7-day. Subsequently, the patients were followed up for 6 months.

Results: Two hundred thirty patients, including 98 with hyponatremia (tolvaptan vs. placebo: 69 vs. 29) finished the study. Tolvaptan did not alter serum sodium levels and survival outcome of decompensated cirrhotic patients without hyponatremia. However, tolvaptan treatment remarkably improved serum sodium levels and six-month survival in patients with hyponatremia. Following tolvaptan treatment, serum sodium levels were restored to normal in 63.8% of patients, whereas in patients receiving placebo, only 36.2% showed the same effect (P < 0.05). Compared to a six-month survival rate of 68.97% in patients receiving placebo, the survival rate in tolvapatan-treated patients was 89.94% (P < 0.05). Furthermore, six-month survival rate in the tolvaptan-treated hyponatremia patients with resolved serum sodium was 81.32%, whereas the survival in those with unresolved serum sodium was only 24% (P < 0.05).

Conclusions: Tolvaptan improves short term survival in most decompensated cirrhotic hyponatremia patients with resolved serum sodium.

Trials registration: Clinical trial one: ClinicalTrials.gov ID: NCT00664014 , Registered on April 14, 2008. Clinical trial two: ClinicalTrials.gov ID: NCT01349335 , Registered on March 5, 2010. Clinical trial three: ClinicalTrials.gov ID: NCT01349348 , Registered on May 4, 2011.

Item Type: Article
Journal or Publication Title: BMC Gastroenterology
Volume: 18
Number: 137
Publisher: BioMed Central
Place of Publication: London
Date Deposited: 25 Oct 2018 12:58
Date: 2018
ISSN: 1471-230X
Page Range: pp. 1-8
Faculties / Institutes: Medizinische Fakultät Mannheim > Medizinische Klinik - Lehrstuhl für Innere Medizin II
Subjects: 610 Medical sciences Medicine
About | FAQ | Contact | Imprint |
OA-LogoDINI certificate 2013Logo der Open-Archives-Initiative